The Postprandial to Fasting Serum C-peptide Ratio is a Predictor of Response to Basal Insulin Supported Oral Antidiabetic drug(s) therapy: A Retrospective Analysis

Introduction Basal insulin is widely recommended for the treatment of type 2 diabetes mellitus (T2DM) patients who are unable to achieve glycemic control with oral antidiabetic drug(s) (OADs). However, some patients are still unable to control their blood glucose levels even when on basal insulin-supported OAD(s) therapy (BOT). The aim of this study was to investigate the factor(s) predicting patient response to BOT.